马健尊;闫东梅;

• 1:吉林大学基础医学院免疫学系

摘要(Abstract)：

卡介苗(Bacille Calmette-Guerin,BCG)是强毒性牛型结核杆菌在特殊人工培养基上经数年传代所获得的减毒牛型结核杆菌活疫苗,其致病能力有所减弱,但仍保留免疫原性,主要用于结核病的防治。BCG灌注疗法一直被认为是经尿道切除非肌层浸润性膀胱癌(non muscle-invasive bladder cancer,NMIBC)最有效的辅助治疗方法,该方法的机制包括BCG的直接作用和间接作用。直接作用是BCG黏附于膀胱并被细胞内化,从而增加肿瘤细胞中具有细胞毒作用的一氧化氮(NO)产生;间接作用是对免疫系统的激活,包括巨噬细胞、中性粒细胞等,从而使这些细胞发挥肿瘤杀伤功能,该过程也与白细胞介素-2(interlukine-2,IL-2)、IL-8、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、IL-10等细胞因子有关。本文就BCG抗肿瘤作用机制的研究进展作一综述。

关键词(KeyWords)： 卡介苗;免疫治疗;膀胱癌;作用机制

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81871245)

作者(Authors): 马健尊;闫东梅;

DOI: 10.13200/j.cnki.cjb.002685

参考文献(References)：

• [1] BALI P,TOUSIF S,DAS G,et al. Strategies to improve BCG vaccine efficacy[J]. Immunotherapy,2015,7(9):945-948.
• [2] BAJIC P,WOLFE A J,GUPTA G N. Old instillations and new implications for bladder cancer:the urinarymicrobiome and intravesical BCG[J]. BJU Int,2019,124(1):7-8.
• [3] SAAD F T,HINCAL E,KAYMAKMZADE B. Dynamics of immune checkpoints,immune system,and BCG in the treatment of superficial bladder cancer[J]. Comput Math Methods Med,2017,2017:3573082.
• [4] DE REIJKE T M,DE BOER L C,STEERENBERG P A,et al. The effects of intravesical pretreatment with pentosan polysulfate on the bacillus Calmette-Guérin induced immune reaction of the guinea pig[J]. J Urol,1994,151(3):746-749.
• [5] COON B G,CRIST S,GONZ LEZ-BONET A M,et al. Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells[J]. Int J Cancer,2012,131(3):591-600.
• [6] ZHAO W,SCHOREY J S,BONG-MASTEK M,et al. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity[J]. Int J Cancer,2000,86(1):83-88.
• [7] THIEL T,RYK C,CHATZAKOS V,et al. Secondary stimulation from Bacillus Calmette-Guérin induced macrophages induce nitric oxideindependent cell-death in bladder cancer cells[J]. Cancer Lett,2014,348(1-2):119-125.
• [8] BEVERS R F M,KURTH K H,SCHAMHART D H J. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer[J]. Br J Cancer,2004,91(4):607-612.
• [9] AUDENET F,FARKAS A M,ANASTOS H,et al. Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer[J]. World J Urol,2018,36(11):1741-1748.
• [10] LIU Q,TIAN Y,ZHAO X,et al. NMAAP1 Expressed in BCGactivated macrophage promotes M1 macrophage polarization[J]. Mol Cells,2015,38(10):886-894.
• [11] SURIANO F,SANTINI D,PERRONE G,et al. Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer[J]. J Exp Clin Cancer Res,2013,32(1):87.
• [12] GUNDRA U M,GIRGIS N M,RUCKERL D,et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct[J].Blood,2014,123(20):e110-122.
• [13] IVANOVA E A,OREKHOV A N. Monocyte activation in immunopathology:cellular test for development of diagnostics and therapy[J]. J Immunol Res,2016,(23):279-293.
• [14] OSTUNI R,KRATOCHVILL F,MURRAY P J,et al. Macrophages and cancer:from mechanisms to therapeutic implications[J]. Trends Immunol,2015,36(4):229-239.
• [15] LIU K,SUN E,LEI M,et al. BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment[J]. Clin Immunol,2019,201:4-14.
• [16] LIU X,DOWELL A C,PATEL P,et al. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin[J]. Future Oncol,2014,10(8):1443-1456.
• [17] KEMP T J,LUDWIG A T,EAREL J K,et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin(BCG)results in the release of functional soluble TRAIL/Apo2L[J]. Blood,2005,106(10):3474-3482.
• [18] DE REIJKE T M,DE BOER E C,KURTH K H,et al. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer:processing,stability and prognostic value[J]. J Urol,1996,155(2):477-482.
• [19] B魻HLE A,BRANDAU S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer[J].J Urol,2003,170(3):964-969.
• [20] MORILLON Y M 2ND,SU Z,SCHLOM J,et al. Temporal changes within the(bladder)tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHSIL12[J]. J Immunother Cancer,2019,7(1):150.
• [21] QU K,GU J,YE Y,et al. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in nonmuscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy:A long-term survival analysis[J]. Oncoimmunology,2017,6(2):e1265719.
• [22] LUDWIG A T,MOORE J M,LUO Y,et al. Tumor necrosis factor-related apoptosis-inducing ligand:a novel mechanism for bacillus Calmette-Guerin-induced antitumor activity[J]. Cancer Res,2004,64(10):3386-3390.
• [23] LUO Y,HAN R,EVANOFF D P,et al. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin(BCG)-induced macrophage cytotoxicity against bladder cancer cells[J]. Clin Exp Immunol,2010,160(3):359-368.
• [24] WANG X,NI S,CHEN Q,et al. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10[J].Cell Biol Int,2017,41(2):177-186.
• [25] NEWTON M R,ASKELAND E J,ANDRESEN E D,et al.Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette-Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity[J]. Clin Exp Immunol,2014,177(1):261-268.
• [26] ZAHOOR H,MIR M C,BARATA P C,et al. Phase II trial of continuous treatment with sunitinib in patients with high-risk(BCG-refractory)non-muscle invasive bladder cancer[J]. Invest New Drugs,2019 Jun 24[Epub ahead of print].
• [27] SHAN G,TANG T,QIAN H,et al. Certain BCG-reactive responses are associated with bladder cancer prognosis[J].Cancer Immunol Immunother,2018,67(5):797-803.
• [28] DENG T,LIU B,DUAN X,et al. Systematic review and cumulative analysis of the combination of mitomycin C plus Bacillus Calmette-Guérin(BCG)for non-muscle-invasive bladder cancer[J]. Sci Rep,2017,7(1):3172.
• [29] MAO M H,HUANG H B,ZHANG X L,et al. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway[J]. Biomed Pharmacother,2018,107:1093-1103.
• [30] WANG Y,LIU J,YANG X,et al. Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer[J]. Onco Targets Ther,2018,11:2891-2899.
• [31] DONIN N M,LENIS A T,HOLDEN S,et al. Immunotherapy for the treatment of urothelial carcinoma[J]. J Urol,2017,197(1):14-22.